NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date (Ascending) | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
51991-0759-90 | 51991-0759 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Oct. 1, 2022 | In Use | ||
55150-0326-01 | 55150-0326 | CLOFARABINE | CLOFARABINE | 1.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Oct. 3, 2022 | In Use | |
55513-0488-02 | 55513-0488 | Sotorasib | LUMAKRAS | 120.0 mg/1 | Chemotherapy | RAS Inhibitor | KRAS G12C | Oral | May 28, 2021 | In Use | |
55513-0488-24 | 55513-0488 | Sotorasib | LUMAKRAS | 120.0 mg/1 | Chemotherapy | RAS Inhibitor | KRAS G12C | Oral | May 28, 2021 | In Use | |
55513-0488-96 | 55513-0488 | Sotorasib | LUMAKRAS | 120.0 mg/1 | Chemotherapy | RAS Inhibitor | KRAS G12C | Oral | May 28, 2021 | In Use | |
60760-0790-12 | 60760-0790 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | July 20, 2022 | In Use | |
60760-0790-21 | 60760-0790 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | July 20, 2022 | In Use | |
55150-0431-01 | 55150-0431 | DACTINOMYCIN | DACTINOMYCIN | 0.5 mg/mL | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intravenous | March 15, 2021 | In Use | |
55150-0928-02 | 55150-0928 | DACTINOMYCIN | DACTINOMYCIN | 0.5 mg/mL | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intravenous | March 15, 2021 | In Use | |
55700-0961-12 | 55700-0961 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 31, 2022 | In Use |
Found 10,000 results in 5 milliseconds — Export these results